# Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients

> **NCT01336062** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peking University** · enrollment: 19 (actual)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Nanoparticle Albumin-Bound Paclitaxel

## Key facts

- **NCT ID:** NCT01336062
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2015-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01336062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01336062, "Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01336062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*